Endocrine metabolic diseases
Conditions
Interventions
Early-time restricted eating:A non-randomised crossover controlled study was conducted in which healthy adults who met the inclusion criteria underwent early time-restricted eating and late time-restr
and a washout period of 2 weeks was carried out in between. The intervention lasts for 2 weeks, with a 2-week washout period
it continues with a late phase of time-restricted eating - starting at 11:00 a.m., eating the second meal at 15:00 a.m., and finishing with the last meal at 19:00 a.m., for a 2-week intervention perio
Late-time restricted eating:Healthy adults on late time-restricted feeding first - daily feeding from 11:00, second meal at 15:00, last meal at 19:00, intervention length two weeks
2-week washout period in between
continue with early time-restricted feeding - daily feeding from 7:00, second meal at 11:00, last meal at 15:00, intervention length two weeks
continue with early time-restricted feeding - daily feeding from 7:00, second meal at 11:00, previous meal at 15:00, intervention length two weeks
continue with early time-restricted feeding - daily feeding from 7:00, second meal at 11:00, previous meal at 15:00, intervention length two weeks. The second meal was eaten at 11:00, and the last mea
Sponsors
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age 18 to 75 years; (2) Healthy people; Fasting blood glucose < 6.1 mmol/l OGTT 2h blood glucose < 7.8 mmol/l HbA1c < 5.7 %. (3) Signed informed consent after fully understanding the study's implementation process.
Exclusion criteria
Exclusion criteria: (1) A history of combined cardiovascular, cerebrovascular, hepatic, renal, hematopoietic and tumour primary diseases and psychiatric disorders; (2) Impaired consciousness or inability to cooperate with treatment; (3) Pregnant or lactating women; (4) Calculated glomerular filtration rate less than 45 ml/min/1.73 m2; (5) History of liver disease (except non-alcoholic fatty liver disease) such as cirrhosis, hepatitis B or C (except in carriers), or alanine aminotransferase (ALT) or aliquot aminotransferase (AST) exceeding the upper limit of the normal range (ULN) by a factor of 3 or total bilirubin exceeding a factor of 2 ULN; (6) History of acute or chronic pancreatitis; (7) Severe chronic infection (e.g., tuberculosis) (8) Severe or unstable heart failure with myocardial infarction within the last six months; (9) History of advanced malignancy and extensive metastatic cancer; (10) Depression, epilepsy, schizophrenia, Alzheimer's disease; (11) Eating disorders or behavioral cognitive difficulties such as malnutrition, alcoholism, anorexia nervosa, and manageable starvation disease; (12) History of AIDS, substance abuse; (13) Being involved in another clinical research trial; (14) Other conditions that the investigator considers inappropriate for enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body Composition Analysis;Indicators of glucose metabolism;Lipid metabolism indicators;lipocalin; | — |
Secondary
| Measure | Time frame |
|---|---|
| melatonin;cortisol;sleep score; | — |
Countries
China
Contacts
Public ContactChao Liu
Endocrinology Department, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine
Outcome results
None listed